Endocyte Inc. (NASDAQ:ECYT) saw unusually-high trading volume on Friday . Approximately 154,084 shares were traded during trading, a decline of 5% from the previous session’s volume of 161,920 shares.The stock last traded at $3.28 and had previously closed at $3.21.

ECYT has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Friday, May 20th. Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Endocyte in a research note on Wednesday, May 4th. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Endocyte in a research note on Tuesday, July 12th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Endocyte in a research note on Wednesday, May 4th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $11.15.

The company’s market capitalization is $139.05 million. The firm’s 50 day moving average price is $3.15 and its 200 day moving average price is $3.41.

Endocyte (NASDAQ:ECYT) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.01. During the same quarter last year, the firm earned ($0.25) EPS. Equities research analysts forecast that Endocyte Inc. will post ($1.12) earnings per share for the current fiscal year.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.